American Society of Nephrology (ASN)

Kidney Health Initiative Urges Investigators to Include People with Kidney Diseases in Clinical Trials for Coronavirus 2019 (COVID-19) Therapies

9-Jun-2020 1:45 PM EDT, by American Society of Nephrology (ASN)

 

Highlights:

  • People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
  • COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
  • All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.

  

Newswise — Washington, DC (June 9, 2020) — Clinical trials often exclude people with kidney diseases. This practice could have significant consequences, if continued, during the Coronavirus – 2019 (COVID-19) pandemic and for the 37 million Americans with kidney diseases who are at high risk of severe disease.

Preliminary studies indicate that people with kidney diseases demonstrate an increased risk (two- to sixteen-fold) for developing severe COVID-19 symptoms. These data support US statistics that show acute kidney injury occurs in up to 5% of hospitalized COVID-19 patients and 50-90% of patients in the intensive care unit. An effective response to the COVID-19 pandemic should include people with kidney diseases.

The KHI Board of Directors considered a variety of issues impacting drug and device development in the kidney community during the COVID-19 pandemic and identified inclusion of people with kidney diseases in clinical trials for COVID-19 therapies as central to improving care. The recent statement, written by members of the Board of Directors is titled “Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials”.

“Given their increased risk, people with kidney diseases deserve to be prioritized in the development of novel therapies for COVID-19,” said Raymond C. Harris, MD, FASN, Co-Chair of KHI, “KHI urges sponsors and investigators to come alongside the US Food and Drug Administration (FDA) and the patient community to expand their research into this vulnerable population.”

The FDA encourages enrollment practices that lead to clinical trials better reflecting the population most likely to use and benefit from the therapy being studied. This can be achieved through novel trial designs or broadening eligibility criteria, when appropriate, to increase enrollment of underrepresented populations. A recent guidance from the FDA titled “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention” explicitly encouraged sponsors to include people with kidney diseases in their COVID-19 trials.   

As the largest consortia in the kidney community and a public-private partnership between the American Society of Nephrology and the FDA, KHI urges all investigators to include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19. This population demonstrates increased risk of exposure, infection, and severe morbidity, and inclusion of people with kidney diseases in trials would benefit all aspects of health care.

Individuals who are interested in learning more about KHI, should contact Melissa West, Acting Vice President for Research, Discovery and Innovation, at mwest@asn-online.org

The Kidney Health Initiative (KHI) is a key part of the newly created ASN Alliance for Kidney Health. KHI is uniquely positioned to realize ASN’s vision of a world without kidney diseases. As a public-private and collaborative partnership with the FDA and more than 100 organizations and companies, KHI catalyzes innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases. Learn more at www.kidneyhealthinitiative.org.

 

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.

 

# # #

 

 




Filters close

Showing results

1120 of 2911
Newswise: Americans actively engaging in collectivism as financial buoy, experts say
Released: 13-Aug-2020 11:25 AM EDT
Americans actively engaging in collectivism as financial buoy, experts say
University of Notre Dame

Karen Richman, University of Notre Dame director of undergraduate studies at the Institute for Latino Studies, and her colleague, found that many people in the U.S. are relying on informal networks of family and friends to stay afloat in a recent study.

Newswise: 240116_web.jpg
Released: 13-Aug-2020 11:20 AM EDT
Researchers identify a protein that may help SARS-CoV-2 spread rapidly through cells
Colorado State University

Eric Ross and Sean Cascarina, biochemistry and molecular biology researchers at Colorado State University, have released a research paper identifying a protein encoded by SARS-CoV-2, the virus that causes COVID-19, that may be associated with the quick spread of the virus through cells in the human body.

Newswise: 240119_web.jpg
Released: 13-Aug-2020 11:05 AM EDT
Public health consequences of policing homelessness
University of Colorado Denver

Two weeks ago, Colorado State Patrol troopers began clearing out nearly 200 residents from homeless encampments that surround the Colorado Capitol.

Released: 13-Aug-2020 10:35 AM EDT
Age discrimination seen @Twitter during #COVID19 pandemic
University of Michigan

The COVID-19 pandemic has created a perfect storm for age discrimination on social media.

Released: 13-Aug-2020 10:15 AM EDT
New COVID-19 Model Reveals Need for Better Travel Restriction Implementation
Rensselaer Polytechnic Institute (RPI)

More strategic and coordinated travel restrictions could have reduced the spread of COVID-19 in the early stages of the pandemic, data confirms. The conclusion, available in preprint on MedRxiv, an online repository of papers that have been screened but not peer reviewed, stems from new modeling conducted by a multidisciplinary team of scientists and engineers at Rensselaer Polytechnic Institute.

Released: 13-Aug-2020 10:05 AM EDT
Four National Organizations Provide Guidance on Maintaining Essential Operations as COVID-19 Pandemic Continues
American Society of Anesthesiologists (ASA)

The recent resurgence of Coronavirus Disease 2019 (COVID-19) has many states near or at bed and intensive care unit (ICU) capacity, and health care facilities’ ability to meet the ongoing needs of surgical patients may be stressed by new influxes of COVID-19 patients admitted to health care facilities. To ensure health care organizations, physicians, and nurses remain prepared to meet these demands to care for patients who undergo recommended essential operations, the American College of Surgeons (ACS), American Society of Anesthesiologists (ASA), Association of periOperative Registered Nurses (AORN) and American Hospital Association (AHA) have developed a Joint Statement: Roadmap for Maintaining Essential Surgery During COVID-19 Pandemic. This joint statement provides a list of principles and considerations to guide physicians, nurses, and hospitals and health systems as they provide essential care to their patients and communities. This joint statement builds on the Joint Statement:

Newswise: COVID-19 Vaccine Candidate Tested at University of Kentucky Shows Positive Preclinical Results
Released: 13-Aug-2020 8:50 AM EDT
COVID-19 Vaccine Candidate Tested at University of Kentucky Shows Positive Preclinical Results
University of Kentucky

PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203.

Released: 13-Aug-2020 8:45 AM EDT
Oxygen Therapy Harms Lung Microbiome in Mice
Michigan Medicine - University of Michigan

New mouse study on the lung microbiome could have implications for treatment of reduced oxygen levels in critically ill patients—including those with COVID-19.

Newswise:Video Embedded slac-scientists-invent-low-cost-emergency-ventilator-and-share-the-design-for-free
VIDEO
Released: 13-Aug-2020 8:45 AM EDT
SLAC scientists invent low-cost emergency ventilator and share the design for free
SLAC National Accelerator Laboratory

Researchers at the Department of Energy’s SLAC National Accelerator Laboratory have invented an emergency ventilator that could help save the lives of patients suffering from COVID-19, the disease caused by novel coronavirus SARS-CoV-2.

Newswise: 240021_web.jpg
Released: 13-Aug-2020 8:35 AM EDT
Scientists identify hundreds of drug candidates to treat COVID-19
University of California, Riverside

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.


Showing results

1120 of 2911

close
3.96562